Skip to main content

A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Eli Lilly and Company

Start Date

June 15, 2017

End Date

June 20, 2020
 

Administered By

Duke Cancer Institute

Awarded By

Eli Lilly and Company

Start Date

June 15, 2017

End Date

June 20, 2020